Andrey Korshunov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2111633/publications.pdf

Version: 2024-02-01

88 papers 12,477 citations

39 h-index 78 g-index

88 all docs 88 docs citations

88 times ranked 13436 citing authors

#	Article	IF	Citations
1	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. Acta Neuropathologica Communications, 2022, 10, 5.	2.4	12
2	Oligosarcomas, IDH-mutant are distinct and aggressive. Acta Neuropathologica, 2022, 143, 263-281.	3.9	18
3	HIP1R and Vimentin immunohistochemistry predict $1\text{p}/19\text{q}$ status in IDH-mutant glioma. Neuro-Oncology, 2022, , .	0.6	4
4	OTHR-41. Amplification of the PLAG family genes â€" PLAGL1 and PLAGL2 â€" is a key feature of a novel embryonal CNS tumor type. Neuro-Oncology, 2022, 24, i156-i156.	0.6	1
5	MEDB-60. Medulloblastoma with extensive nodularity mimics cerebellar development and differentiates along the granular precursor lineage. Neuro-Oncology, 2022, 24, i120-i120.	0.6	O
6	ETMR-06. Molecular and clinical characteristics of CNS tumors with <i>BCOR(L1</i>) fusion/internal tandem duplication. Neuro-Oncology, 2022, 24, i50-i50.	0.6	2
7	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	0.6	1
8	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. Neuro-Oncology, 2022, 24, i154-i154.	0.6	0
9	MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate. Neuro-Oncology, 2022, 24, i114-i115.	0.6	0
10	ATRT-10. Single-cell transcriptional profiling of ATRTs reveals heterogeneous signatures of tumor and non-malignant cell populations. Neuro-Oncology, 2022, 24, i4-i5.	0.6	0
11	RARE-15. Astroblastoma, <i>MN1</i> altered comprises two molecularly and clinically distinct subgroups defined by the fusion partners <i>BEND2</i> and <i>CXXC5</i> . Neuro-Oncology, 2022, 24, i12-i13.	0.6	1
12	CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model. Oncogene, 2021, 40, 396-407.	2.6	35
13	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathologica, 2021, 141, 85-100.	3.9	52
14	Accurate calling of <i>KIAA1549â€BRAF</i> fusions from DNA of human brain tumours using methylation arrayâ€based copy number and gene panel sequencing data. Neuropathology and Applied Neurobiology, 2021, 47, 406-414.	1.8	12
15	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i> . Neuro-Oncology, 2021, 23, 34-43.	0.6	7 5
16	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma. Neuro-Oncology Advances, 2021, 3, vdab002.	0.4	2
17	A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors. Cancers, 2021, 13, 230.	1.7	13
18	The age of adult pilocytic astrocytoma cells. Oncogene, 2021, 40, 2830-2841.	2.6	6

#	Article	IF	Citations
19	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. Acta Neuropathologica, 2021, 142, 179-189.	3.9	24
20	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	0.6	22
21	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	3.9	33
22	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	3.9	34
23	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. Nature Communications, 2021, 12, 5530.	5.8	24
24	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathologica, 2021, 142, 1065-1069.	3.9	16
25	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. Acta Neuropathologica, 2021, 142, 873-886.	3.9	12
26	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	5.8	237
27	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Science Translational Medicine, 2021, 13, eabc0497.	5.8	29
28	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathologica, 2020, 139, 193-209.	3.9	83
29	Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. Acta Neuropathologica, 2020, 139, 403-406.	3.9	9
30	YAP1-fusions in pediatric NF2-wildtype meningioma. Acta Neuropathologica, 2020, 139, 215-218.	3.9	45
31	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. Acta Neuropathologica, 2020, 139, 243-257.	3.9	50
32	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell, 2020, 183, 1617-1633.e22.	13.5	93
33	ETMR: a tumor entity in its infancy. Acta Neuropathologica, 2020, 140, 249-266.	3.9	47
34	Pilocytic astrocytoma demethylation and transcriptional landscapes link bZIP transcription factors to immune response. Neuro-Oncology, 2020, 22, 1327-1338.	0.6	10
35	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. Journal of Clinical Oncology, 2020, 38, 2028-2040.	0.8	58
36	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	7.7	157

#	Article	IF	Citations
37	MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS. Neuro-Oncology, 2020, 22, iii413-iii413.	0.6	0
38	MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN). Neuro-Oncology, 2020, 22, iii410-iii410.	0.6	0
39	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. Acta Neuropathologica, 2019, 138, 827-835.	3.9	42
40	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathologica Communications, 2019, 7, 163.	2.4	37
41	Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells. Blood Advances, 2019, 3, 1092-1102.	2.5	25
42	Acyl-CoA-Binding Protein Drives Glioblastoma Tumorigenesis by Sustaining Fatty Acid Oxidation. Cell Metabolism, 2019, 30, 274-289.e5.	7.2	115
43	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. Acta Neuropathologica, 2019, 137, 837-846.	3.9	43
44	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	13.7	94
45	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. Cancer Cell, 2019, 35, 95-110.e8.	7.7	65
46	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. Clinical Cancer Research, 2019, 25, 1851-1866.	3.2	55
47	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	3.9	298
48	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathologica, 2018, 135, 635-638.	3.9	17
49	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	13.7	1,872
50	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	3.9	190
51	Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3392-3397.	3.3	34
52	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathology, 2018, 28, 656-662.	2.1	89
53	LGG-11. REGULATION OF ONCOGENE-INDUCED SENESCENCE IN PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2018, 20, i106-i106.	0.6	0
54	Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors. Nature Communications, 2018, 9, 4760.	5.8	66

#	Article	IF	CITATIONS
55	Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. Cancer Cell, 2018, 34, 379-395.e7.	7.7	104
56	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. Acta Neuropathologica, 2018, 136, 293-302.	3.9	56
57	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathologica, 2018, 136, 181-210.	3.9	308
58	Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. Acta Neuropathologica, 2018, 136, 339-343.	3.9	37
59	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	5.1	268
60	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	3.9	104
61	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathologica, 2017, 134, 507-516.	3.9	144
62	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro-Oncology, 2017, 19, 1607-1617.	0.6	39
63	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro-Oncology, 2017, 19, 1183-1194.	0.6	31
64	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	13.7	787
65	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathologica, 2017, 134, 705-714.	3.9	168
66	Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow. Methods, 2017, 114, 60-73.	1.9	15
67	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget, 2017, 8, 11460-11479.	0.8	43
68	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. Brain Pathology, 2016, 26, 506-516.	2.1	14
69	Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas—Same Entity or First Cousins?. Brain Pathology, 2016, 26, 215-223.	2.1	95
70	Differential nuclear <scp>ATRX</scp> expression in sarcomas. Histopathology, 2016, 68, 738-745.	1.6	19
71	Telomere dysfunction and chromothripsis. International Journal of Cancer, 2016, 138, 2905-2914.	2.3	42
72	Somatic mutations of <i>DICER1</i> and <i>KMT2D</i> are frequent in intraocular medulloepitheliomas. Genes Chromosomes and Cancer, 2016, 55, 418-427.	1.5	34

#	Article	IF	CITATIONS
73	Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients. Journal of Neuropathology and Experimental Neurology, 2016, 75, 408-414.	0.9	35
74	Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells. American Journal of Pathology, 2016, 186, 446-459.	1.9	32
75	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. Neuro-Oncology, 2016, 18, 790-796.	0.6	67
76	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	7.7	438
77	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	13.5	702
78	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. Neuropathology, 2015, 35, 538-544.	0.7	38
79	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	7.7	933
80	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nature Communications, 2015, 6, 10001.	5.8	266
81	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathologica, 2015, 129, 669-678.	3.9	277
82	Intraocular Medulloepitheliomas and Embryonal Tumors With Multilayered Rosettes of the Brain: Comparative Roles of LIN28A and C19MC. American Journal of Ophthalmology, 2015, 159, 1065-1074.e1.	1.7	28
83	Targeting Self-Renewal in High-Grade Brain Tumors Leads to Loss of Brain Tumor Stem Cells and Prolonged Survival. Cell Stem Cell, 2014, 15, 185-198.	5. 2	123
84	Spinal metastasis of gliosarcoma: Array-based comparative genomic hybridization for confirmation of metastatic spread. Journal of Clinical Neuroscience, 2014, 21, 1945-1950.	0.8	8
85	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathologica, 2013, 125, 913-916.	3.9	244
86	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 2013, 126, 907-915.	3.9	254
87	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	7.7	1,551
88	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathologica, 2011, 121, 397-405.	3.9	914